{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:10:26Z","timestamp":1768522226668,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartandlung.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart & Lung"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.hrtlng.2024.12.010","type":"journal-article","created":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T19:16:36Z","timestamp":1736018196000},"page":"250-257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["The cardiovascular effects of long-acting bronchodilators inhalers and inhaled corticosteroids purchases among asthma and COPD patients"],"prefix":"10.1016","volume":"70","author":[{"given":"Niv","family":"Lev-Ari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernice","family":"Oberman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiri","family":"Kushnir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noga","family":"Yosef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4327-1084","authenticated-orcid":false,"given":"Dekel","family":"Shlomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hrtlng.2024.12.010_bib0001","unstructured":"2023 GOLD Report - Global Initiative for Chronic Obstructive Lung Disease - GOLD. Accessed February 25, 2024. https:\/\/goldcopd.org\/2023-gold-report-2\/."},{"key":"10.1016\/j.hrtlng.2024.12.010_bib0002","unstructured":"2023 GINA Main Report - Global Initiative for Asthma - GINA. Accessed July 24, 2023. https:\/\/ginasthma.org\/wp-content\/uploads\/2023\/07\/GINA-2023-Full-report-23_07_06-WMS.pdf."},{"issue":"9","key":"10.1016\/j.hrtlng.2024.12.010_bib0003","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1345\/aph.10379","article-title":"Compliance from self-reported versus pharmacy claims data with metered-dose inhalers","volume":"35","author":"SR","year":"2001","journal-title":"Ann Pharmacother"},{"issue":"3","key":"10.1016\/j.hrtlng.2024.12.010_bib0004","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1513\/AnnalsATS.201509-600PS","article-title":"Why Don't Our Patients with Chronic Obstructive Pulmonary Disease Listen to Us? The Enigma of Nonadherence","volume":"13","author":"FC","year":"2016","journal-title":"Ann Am Thorac Soc."},{"issue":"1","key":"10.1016\/j.hrtlng.2024.12.010_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1465-9921-11-122","article-title":"Characterisation of COPD heterogeneity in the ECLIPSE cohort","volume":"11","author":"Agusti","year":"2010","journal-title":"Respir Res"},{"issue":"2","key":"10.1016\/j.hrtlng.2024.12.010_bib0006","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1161\/01.HYP.0000172753.96583.e1","article-title":"Effects of noncardiovascular comorbidities on antihypertensive use in elderly hypertensives","volume":"46","author":"Wang","year":"2005","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.hrtlng.2024.12.010_bib0007","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1440-1843.2011.02118.x","article-title":"Link between chronic obstructive pulmonary disease and coronary artery disease: Implication for clinical practice","volume":"17","author":"Boschetto","year":"2012","journal-title":"Respirology"},{"issue":"4","key":"10.1016\/j.hrtlng.2024.12.010_bib0008","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1183\/09031936.00012408","article-title":"Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD","volume":"32","author":"Mannino","year":"2008","journal-title":"European Respiratory Journal"},{"issue":"167","key":"10.1016\/j.hrtlng.2024.12.010_bib0009","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0202-2022","article-title":"Strength of association between comorbidities and asthma: a meta-analysis","volume":"32","author":"Rogliani","year":"2023","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.hrtlng.2024.12.010_bib0010","doi-asserted-by":"crossref","unstructured":"Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-Dose Inhaled Corticosteroids and the Prevention of Death from Asthma. 2009;343(5):332-336. 10.1056\/NEJM200008033430504.","DOI":"10.1056\/NEJM200008033430504"},{"key":"10.1016\/j.hrtlng.2024.12.010_bib0011","doi-asserted-by":"crossref","unstructured":"Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. Vol 356.; 2007. www.nejm.org.","DOI":"10.1056\/NEJMoa063070"},{"issue":"18","key":"10.1016\/j.hrtlng.2024.12.010_bib0012","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.hrtlng.2024.12.010_bib0013","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1164\/rccm.201911-2207OC","article-title":"Reduction in all-cause mortality with fluticasone furoate\/umeclidinium\/vilanterol in patients with chronic obstructive pulmonary disease","volume":"201","author":"Lipson","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.hrtlng.2024.12.010_bib0014","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/FJC.0000000000000705","article-title":"Correlation of Inhaled Long-Acting Bronchodilators With Adverse Cardiovascular Outcomes in Patients With Stable COPD: A Bayesian Network Meta-Analysis of Randomized Controlled Trials","volume":"74","author":"Wu","year":"2019","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.hrtlng.2024.12.010_bib0015","doi-asserted-by":"crossref","unstructured":"Li C, Cheng W, Guo J, Guan W. Relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD: a meta-analysis and systematic review of 43 randomized trials. Published online 2019. 10.2147\/COPD.S198288.","DOI":"10.2147\/COPD.S198288"},{"key":"10.1016\/j.hrtlng.2024.12.010_bib0016","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.2147\/COPD.S358927","article-title":"Association between Inhaled \u03b22-agonists Initiation and Risk of Major Adverse Cardiovascular Events: A Population-based Nested Case-Control Study","volume":"17","author":"Amegadzie","year":"2022","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"2","key":"10.1016\/j.hrtlng.2024.12.010_bib0017","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/jamainternmed.2017.7720","article-title":"Association of Cardiovascular Risk With Inhaled Long-Acting Bronchodilators in Patients With Chronic Obstructive Pulmonary Disease: A Nested Case-Control Study","volume":"178","author":"Wang","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"10030","key":"10.1016\/j.hrtlng.2024.12.010_bib0018","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(16)30069-1","article-title":"Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): A double-blind randomised controlled trial","volume":"387","author":"Vestbo","year":"2016","journal-title":"The Lancet"},{"issue":"12","key":"10.1016\/j.hrtlng.2024.12.010_bib0019","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1001\/jama.300.12.1439","article-title":"Inhaled Anticholinergics and Risk of Major Adverse Cardiovascular Events in Patients With Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis","volume":"300","author":"Singh","year":"2008","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.hrtlng.2024.12.010_bib0020","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","article-title":"A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease","volume":"15","author":"Tashkin","year":"2008","journal-title":"n engl j med"},{"key":"10.1016\/j.hrtlng.2024.12.010_bib0021","doi-asserted-by":"crossref","unstructured":"Jing X, Li Y, Xu J, Turner AM. Risk of Cardiovascular Events Associated with Inhaled Corticosteroid Treatment in Patients with Chronic Obstructive Pulmonary Disease: A Meta-Analysis. Published online 2018. 10.1155\/2018\/7097540.","DOI":"10.1155\/2018\/7097540"},{"issue":"2","key":"10.1016\/j.hrtlng.2024.12.010_bib0022","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00302-2022","article-title":"Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis","volume":"61","author":"Yang","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.hrtlng.2024.12.010_bib0023","unstructured":"Drug Safety Information for Heathcare Professionals >Early Communication about an Ongoing Safety Review of Tiotropium (marketed as Spiriva HandiHaler). Accessed December 8, 2023. https:\/\/wayback.archive-it.org\/7993\/20170406045706\/https:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/ucm070651.htm."},{"key":"10.1016\/j.hrtlng.2024.12.010_bib0024","unstructured":"Drug Safety Information for Heathcare Professionals >Follow-Up to the October 2008 Updated Early Communication about an Ongoing Safety Review of Tiotropium (marketed as Spiriva HandiHaler). Accessed December 8, 2023. https:\/\/wayback.archive-it.org\/7993\/20170406045704\/https:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/ucm197429.htm."},{"issue":"1","key":"10.1016\/j.hrtlng.2024.12.010_bib0025","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1378\/chest.09-0011","article-title":"Cardiovascular safety of tiotropium in patients with COPD","volume":"137","author":"Celli","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.hrtlng.2024.12.010_bib0026","doi-asserted-by":"crossref","unstructured":"Samp JC, Joo MJ, Schumock GT, Calip GS, Pickard AS, Lee TA. Risk of Cardiovascular and Cerebrovascular Events in COPD Patients Treated With Long-Acting \u03b22-Agonist Combined With a Long-Acting Muscarinic or Inhaled Corticosteroid. 2017;51(11):945-953. 10.1177\/1060028017719716.","DOI":"10.1177\/1060028017719716"},{"key":"10.1016\/j.hrtlng.2024.12.010_bib0027","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.rmed.2014.05.014","article-title":"Inhaled beta-2-agonists\/muscarinic antagonists and acute myocardial infarction in COPD patients","volume":"108","author":"Rottenkolber","year":"2014","journal-title":"Respir Med"}],"container-title":["Heart & Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014795632400253X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014795632400253X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T22:23:51Z","timestamp":1757111031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014795632400253X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":27,"alternative-id":["S014795632400253X"],"URL":"https:\/\/doi.org\/10.1016\/j.hrtlng.2024.12.010","relation":{},"ISSN":["0147-9563"],"issn-type":[{"value":"0147-9563","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The cardiovascular effects of long-acting bronchodilators inhalers and inhaled corticosteroids purchases among asthma and COPD patients","name":"articletitle","label":"Article Title"},{"value":"Heart & Lung","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hrtlng.2024.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}